A股異動丨瑞普生物漲停 農業部印發動物強制免疫計劃
格隆匯1月13日丨瑞普生物(300119.SZ)漲停,報17.9元,總市值72.4億元。

農業農村部印發《2020年國家動物疫病強制免疫計劃》。《計劃》要求,高致病性禽流感、口蹄疫、小反芻獸疫、布魯氏菌病、包蟲病的羣體免疫密度應常年保持在90%以上,其中應免畜禽免疫密度應達到100%。高致病性禽流感、口蹄疫和小反芻獸疫免疫抗體合格率應常年保持在70%以上。我國動物保健行業正處於規模化加速期階段,具體表現為小型養殖場數量的快速減少和大型養殖場數量的快速增加。養殖場規模越大,對生物防疫的重視程度越高,是我國獸藥市場規模提升的重要推動力。獸藥發展報告顯示,我國獸藥市場規模已接近500億元,較2009年規模接近翻倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.